Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, Texas.
Department of Neurology, University of California, San Francisco, San Francisco, California.
Hum Mutat. 2018 May;39(5):666-675. doi: 10.1002/humu.23400. Epub 2018 Jan 25.
Heterozygous variants in the arginine-glutamic acid dipeptide repeats gene (RERE) have been shown to cause neurodevelopmental disorder with or without anomalies of the brain, eye, or heart (NEDBEH). Here, we report nine individuals with NEDBEH who carry partial deletions or deleterious sequence variants in RERE. These variants were found to be de novo in all cases in which parental samples were available. An analysis of data from individuals with NEDBEH suggests that point mutations affecting the Atrophin-1 domain of RERE are associated with an increased risk of structural eye defects, congenital heart defects, renal anomalies, and sensorineural hearing loss when compared with loss-of-function variants that are likely to lead to haploinsufficiency. A high percentage of RERE pathogenic variants affect a histidine-rich region in the Atrophin-1 domain. We have also identified a recurrent two-amino-acid duplication in this region that is associated with the development of a CHARGE syndrome-like phenotype. We conclude that mutations affecting RERE result in a spectrum of clinical phenotypes. Genotype-phenotype correlations exist and can be used to guide medical decision making. Consideration should also be given to screening for RERE variants in individuals who fulfill diagnostic criteria for CHARGE syndrome but do not carry pathogenic variants in CHD7.
精氨酸-谷氨酸二肽重复基因(RERE)中的杂合变异已被证明可导致伴有或不伴有脑、眼或心脏异常的神经发育障碍(NEDBEH)。在这里,我们报告了 9 名患有 NEDBEH 的患者,他们携带 RERE 中的部分缺失或有害序列变异。在所有可获得父母样本的情况下,这些变异均被发现为新生突变。对患有 NEDBEH 的个体的数据进行分析表明,与可能导致单倍不足的功能丧失变异相比,影响 RERE 的 Atrophin-1 结构域的点突变与结构性眼部缺陷、先天性心脏缺陷、肾脏异常和感觉神经性听力损失的风险增加相关。RERE 致病性变异的高百分比影响 Atrophin-1 结构域中的富含组氨酸区域。我们还在该区域鉴定出一种重复的两个氨基酸的重复,与 CHARGE 综合征样表型的发生相关。我们得出结论,影响 RERE 的突变导致一系列临床表型。存在基因型-表型相关性,可以用于指导医疗决策。对于符合 CHARGE 综合征诊断标准但不携带 CHD7 致病性变异的个体,也应考虑筛查 RERE 变异。